Company Filing History:
Years Active: 2009
Title: Mary Ellen Rybak: Innovator in Cancer Treatment
Introduction
Mary Ellen Rybak is a notable inventor based in Princeton, NJ (US). She has made significant contributions to the field of cancer treatment through her innovative research and development. Her work focuses on combining existing therapies to enhance their effectiveness against cancer.
Latest Patents
Mary Ellen Rybak holds a patent for a method that combines ET-743 and a 5-fluorouracil pro-drug for cancer treatment. This patent outlines methods of treating a human body for cancer by administering a therapeutic amount of capecitabine in combination with ET-743. The dosage range for ET-743 is specified between 0.75 and 1.4 mg/m, while the effective therapeutic amount of capecitabine is administered in a range of 1500 to 2500 mg/m/day.
Career Highlights
Throughout her career, Mary Ellen Rybak has been associated with Pharma Mar, S.A.U., a company dedicated to the research and development of innovative therapies for cancer treatment. Her work has contributed to advancing the understanding and treatment of various cancers.
Collaborations
Due to space constraints, the collaborations section will be omitted.
Conclusion
Mary Ellen Rybak's contributions to cancer treatment through her innovative patent demonstrate her commitment to improving patient outcomes. Her work continues to inspire advancements in the medical field.